HIV gene expression is subject to a transcriptional checkpoint, whereby negative transcription elongation factors induce an elongation block that is overcome by HIV Tat protein in conjunction with P-TEFb. P-TEFb is a cyclin-dependent kinase that catalyzes Tat mRNA processing plays an important role in the expression of eukaryotic genes, and the earliest modification event is the formation of the 5Ј-terminal m 7
HIV gene expression is subject to a transcriptional checkpoint, whereby negative transcription elongation factors induce an elongation block that is overcome by HIV Tat protein in conjunction with P-TEFb. P-TEFb is a cyclin-dependent kinase that catalyzes Tat mRNA processing plays an important role in the expression of eukaryotic genes, and the earliest modification event is the formation of the 5Ј-terminal m 7 GpppN cap. Capping entails a series of three enzymatic reactions: (i) RNA triphosphatase removes the ␥ phosphate from the 5Ј-triphosphate end of the nascent mRNA to form a diphosphate terminus; (ii) RNA guanylyltransferase transfers GMP from GTP to the diphosphate RNA terminus to form GpppRNA; and (iii) RNA (guanine-7)-methyltransferase adds a methyl group to the N7 position of the cap guanine (1) . RNA capping is essential for cell growth, i.e. mutations of the triphosphatase, guanylyltransferase, or methyltransferase components of the capping apparatus that abrogate their catalytic activity are lethal in vivo (2) (3) (4) (5) (6) (7) . The m 7 G cap facilitates translation initiation (8) . Failure to cap pre-mRNAs results in their accelerated decay through the agency of a 5Ј exoribonuclease (9) .
Capping occurs shortly after transcription initiation when the 5Ј-end of the nascent RNA chain is extruded from the RNA-binding pocket of the elongating RNA polymerase (10 -12) . Capping of cellular RNAs in vivo is specific to transcripts synthesized by RNA polymerase II (Pol II) 1 (13, 14) . It has been suggested that this specific targeting is achieved through direct physical interaction of one or more components of the capping apparatus with the phosphorylated CTD of the largest subunit of Pol II (15) (16) (17) (18) (19) (20) (21) . The CTD is unique to Pol II and consists of a tandemly repeated heptapeptide motif with the consensus sequence YSPTSPS that is differentially phosphorylated during the transcription cycle (22) . Phosphorylation of the CTD correlates with the release of preinitiation complexes from the promoter and recruitment of the capping enzyme to the transcription elongation complex. In the budding yeast Saccharomyces cerevisiae, the guanylyltransferase (Ceg1) and methyltransferase (Abd1) bind directly to the phosphorylated CTD (15, 17) . The mammalian capping enzyme, Mce1, a bifunctional 597-amino acid polypeptide with both RNA triphosphatase and guanylyltransferase activities, binds to the phosphorylated CTD but not to an unphosphorylated CTD (15, 16, 19, 21) . Binding to CTD phosphorylated at Ser-5 of the YSPTSPS heptad stimulates the guanylyltransferase activity of Mce1 (21, 23) . Although interaction between Pol II and capping enzymes offers an elegant explanation of the specific targeting of capping enzyme to nascent pre-mRNAs, it is conceivable that other factors are also involved in linking capping to transcription. For example, it was reported that hSpt5, the human homolog of yeast elongation factor Spt5, interacts directly with the mammalian capping enzyme and stimulates its guanylyltransferase activity (23) . hSpt5 also plays a role in Tat transactivation of HIV-1 gene expression at the level of transcription elongation (24, 25) .
HIV-1 Tat is a small RNA-binding protein required for efficient transcription of HIV genes. Tat binds specifically to a structured RNA element, TAR, located at the 5Ј-end of the nascent HIV transcript. Tat contains two important functional domains: an arginine-rich region that mediates the binding of Tat to TAR RNA and an activation domain that mediates interactions with cellular factors. Tat functions through TAR to control an early step in transcription elongation that is sensitive to protein kinase inhibitors and requires the Pol II CTD (26) . Tat increases the processivity of RNA polymerase complexes that would otherwise prematurely terminate. This function of Tat is predicated on its ability to enhance the activity of a positive transcription elongation factor, P-TEFb (27) .
Components of the P-TEFb complex required for its activity include a catalytic protein kinase subunit Cdk9 (previously known as PITALRE) (28, 29) and regulatory subunits cyclin T1, cyclin T2a, or cyclin T2b, which associate with Cdk9 and increase its kinase activity (29 -31) . Cyclin T1 interacts directly with the activation domain of Tat. When the proteins are bound to TAR RNA, Tat interacts with the bulge region, whereas cyclin T1 binds to the loop segment (31) . Phosphorylation of the Pol II CTD by P-TEFb kinase is stimulated by Tat and leads to the formation of processive transcription elongation complexes.
Because Tat transactivation and capping are both correlated with CTD phosphorylation at an early stage of transcription elongation, it is conceivable that Tat may interact physically or functionally with mammalian capping enzyme. Here, we show a direct association between Tat and Mce1 in vitro. We find that Tat stimulates mRNA capping in vitro by enhancing the triphosphatase and guanylyltransferase activities of Mce1. Moreover, Tat stimulates the capping of TAR mRNA, which is not guanylylated efficiently by Mce1, presumably because the 5Ј-terminus is encompassed within a stable RNA hairpin. We suggest a model whereby Tat stimulation of TAR mRNA capping contributes to the activation of HIV gene expression.
EXPERIMENTAL PROCEDURES

Expression and Purification of Recombinant Wild-type and Mutant
Tat-Recombinant wild-type HIV-1 Tat, hemagglutinin (HA)-tagged Tat, and Tat deletion mutants were expressed in Escherichia coli as glutathione S-transferase (GST) fusion proteins. These fusion proteins consisted of an N-terminal GST moiety followed by a thrombin cleavage site and variable C-terminal polypeptides segments comprising wildtype Tat-(1-86) with or without HA tag; Tat⌬2/36 (a deletion from amino acids 2 to 36 in the transactivation domain); Tat48⌬ (a deletion of amino acids 49 -86 including the RNA binding domain). Recombinant fusion proteins were purified to apparent homogeneity from bacterial lysates by glutathione-Sepharose affinity chromatography. Briefly, lysates were mixed with a 1-ml slurry of glutathione-Sepharose beads (Amersham Pharmacia Biotech) for 1 h at 4°C. The beads were then poured into a column and washed with 20 ml of PBS (136 mM NaCl, 2.6 mM KCl, 10 mM Na 2 HPO 4 , 1.76 mM KH 2 PO 4 , pH 7.4) containing 1% Triton X-100, 1 mM EDTA, and 50 g/ml phenylmethylsulfonyl fluoride. The immobilized GST⅐Tat beads were used in protein binding assays described below. Alternatively, the Tat proteins were recovered from glutathione-Sepharose beads by thrombin cleavage according to previously described procedures (47) . The eluted Tat proteins were stored in buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM DTT, and 2.5 mM CaCl 2 at Ϫ80°C.
Recombinant Capping Enzymes-Full-length mouse capping enzyme Mce1, the N-terminal RNA triphosphatase domain Mce1-(1-210), and the C-terminal RNA guanylyltransferase domain Mce1-(211-597) were produced in bacteria as N-terminal His-tagged fusions and purified as described (19) .
In Vitro Assay of the Binding of GST⅐Tat to Mammalian Capping Enzyme-Reaction mixtures containing 3-5 g of the wild-type or mutant (⌬2/36, 48⌬) GST⅐Tat proteins bound to glutathione-Sepharose beads and 1 g of the wild-type or mutant Mce1 proteins in 300 l of binding buffer (20 mM Tris-HCl, pH 7.9, 1% Triton X-100, 0.5% Nonidet P-40, 5 mM DTT, 0.2 mM ZnCl 2 , 0.1% bovine serum albumin) supplemented with a protease inhibitor mixture (Roche Molecular Biochemicals) were incubated at 4°C for 2 h. The beads were washed four times in 600 l of washing buffer (30 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM CaCl 2 , 5 mM DTT) and then resuspended in 200 l of washing buffer and split into two equal aliquots. One of the aliquots was treated with 10 units of thrombin (Amersham Pharmacia Biotech) for 10 min at room temperature. Thrombin digestion was then quenched by adding 20 g of phenylmethylsulfonyl fluoride. The second aliquot was not treated with thrombin. The beads were then separated from the supernatant by centrifugation. The supernatant fractions were resolved by SDS-PAGE. The protein contents of the gel were transferred to a polyvinylidene difluoride membrane that was then immunoblotted with rabbit antiserum raised against the guanylyltransferase domain Mce1-(211-597). Immune complexes were detected by using an ECL Western blotting kit according to the instructions of the vendor (Amersham Pharmacia Biotech). The beads were washed six times with 1 ml of binding buffer A, and the bound proteins were then stripped from the beads by boiling in 25 l of SDS-PAGE loading buffer (50 mM Tris-HCl, pH 6.8, 12% glycerol, 4% SDS, 100 mM DTT, and 0.01% Coomassie Blue G-250). Polypeptides were resolved on 8% polyacrylamide gels. The gel contents were transferred to a polyvinylidene difluoride membrane, and Tat protein was detected by immunoblotting with a biotin-conjugated antibody against the HA tag. The blot was developed using a chemiluminescence kit.
In Vitro Assay of the Binding of HA⅐Tat to the Triphosphatase and Guanylyltransferase Domains of Mammalian Capping
Guanylyltransferase Assay-Guanylyltransferase activity of capping enzyme was assayed by the formation of the covalent enzyme-GMP intermediate. Reaction mixtures (20 l) containing 50 mM Tris-HCl, pH 8.0, 5 mM DTT, 5 mM MgCl 2 , 1.25 M [␣-
32 P]GTP, and capping enzyme and Tat proteins as specified were incubated for 15 min at 37°C. The reaction was halted by addition of SDS to 1% final concentration. The reaction mixtures were analyzed by SDS-PAGE. Capping enzyme-[ 32 P]GMP complexes were visualized by autoradiography and quantified by scanning the gel with a phosphorimager.
RNA Triphosphatase Assay-RNA triphosphatase activity was assayed by liberation of 32 P i from [␥-
32 P]GTP-labeled poly(A) RNA synthesized by T7 RNA polymerase transcription. The template strand encoded the sequence for poly(A) RNA starting with G at position ϩ1. In vitro transcription reactions were carried out as described previously (48) in the presence of [␥-32 P]GTP. 5Ј-GTP-terminated 29-mer poly(A) was purified on a 15% polyacrylamide, 7 M urea denaturing gel. RNA triphosphatase reaction mixtures (10 l) containing 50 mM Tris-HCl, pH 8.0, 5 mM DTT, 10 pmol of 5Ј-GTP-terminated poly(A), and capping enzyme and Tat proteins as specified were incubated for 15 min at 37°C. The reaction was halted by addition of 1 l of 88% formic acid. Aliquots of the mixtures were applied to a polyethyleneimine-cellulose TLC plate, which was developed with 0.75 M potassium phosphate (pH 4.3). The release of 32 P i was quantified by scanning the TLC plate with a phosphorimager.
RNA Capping Assay-Triphosphate-terminated 17-mer RNA with no apparent secondary structure and TAR RNA containing a bulge and loop region (see Fig. 7A ) were prepared by in vitro T7 polymerase transcription and then purified by electrophoresis through a 20% polyacrylamide, 7 M urea gel as described previously (48) . [ The mixtures were extracted with phenol/chloroform/isoamyl alcohol (25: 24:1) and then with chloroform. RNAs were recovered by ethanol precipitation and then analyzed by electrophoresis through a 15% polyacrylamide gel containing 7 M urea in Tris-Borate-EDTA. Labeled RNA products were visualized by autoradiography. The internally labeled capped RNA product migrated more slowly than the uncapped substrate RNA. The extent of capping was quantitated by scanning the gel with a phosphorimager.
RESULTS
Tat Directly Interacts with Mammalian Capping Enzyme in
Vitro-To test for interaction between Tat and mammalian capping enzyme, a purified GST⅐Tat fusion protein was linked to glutathione-Sepharose beads, and the beads were incubated with purified recombinant full-length Mce1. After washing the beads with buffer to remove unbound protein, the bound Mce1 was recovered from the beads by treatment with thrombin, which cleaved the GST⅐Tat fusion protein between the GST and Tat domains (Fig. 1A) . Released Mce1 was detected in the supernatant fraction by immunoblotting with antiserum raised against the C-terminal guanylyltransferase domain (Fig. 1B,  lane 3) . Mce1 was not detected in the supernatant when the thrombin cleavage step was omitted (Fig. 1B, lane 2) . Alanine mutations of the active site cysteine of the RNA triphosphatase domain of Mce1 (C126A) or the active site lysine of the guanylyltransferase domain of Mce1 (K294A) that abrogate the triphosphatase and guanylyltransferase activities, respectively, did not interfere with the binding of Mce1 to immobilized Tat (Fig. 1B, lanes 6 and 9) . These results indicate that mammalian capping enzyme can interact directly with Tat in vitro independent of the competence of Mce1 to catalyze phosphoryl or nucleotidyl transfer.
The C-terminal Segment of Tat Containing the RNA Binding Domain Suffices for Binding to Mammalian Capping Enzyme-Tat protein can be divided into two major functional domains ( Fig. 2A) . The transactivation domain (amino acids 1-48) is required for recruitment of cyclin T1 by Tat to the HIV-1 long terminal repeat (LTR) promoter (31) . The C-terminal domain (amino acids 49 -86) includes a basic region and is required for both RNA binding and nuclear localization of Tat (32) . Two truncated versions of Tat, Tat⌬2/36 and Tat48⌬, which are deleted in the transactivation domain and RNA binding domain, respectively, were expressed as GST fusion proteins and tested for binding to the guanylyltransferase domain of mammalian capping enzyme, Mce1-211-597). The guanylyltransferase bound to beads containing immobilized wildtype Tat and Tat⌬2/36 (Fig. 2B, lanes 3 and 5) , but not to Tat48⌬ (Fig. 2B, lane 7) . Similar results were obtained for binding of full-length Mce1 to the truncated Tat proteins (data not shown). We conclude that the Tat segment from amino acids 37-86 suffices for the binding of capping enzyme and that the transactivation domain per se does not interact with capping enzyme or its guanylyltransferase component.
Tat Binding Stimulates the Activity of Mammalian Guanylyltransferase-Are there functional consequences for the interaction of mammalian capping enzyme with Tat? To address this question, we tested the effects of full-length Tat and truncated Tat derivatives on the guanylyltransferase and triphosphatase activities of Mce1. The 597-amino acid mammalian capping enzyme consists of an N-terminal triphosphatase domain (amino acids 1-210) and a C-terminal guanylyltransferase domain (amino acids 211-597). The guanylyltransferase component of the enzyme catalyzes two sequential nucleotidyl transfer reactions involving a covalent enzyme-guanylate intermediate (33) . In the first partial reaction, nucleophilic attack on the ␣-phosphate of GTP by enzyme results in liberation of pyrophosphate and formation of a covalent adduct in which GMP is linked via a phosphoamide bond to the ⑀-amino group of a Lys-294 (16, 19) . The nucleotide is then transferred to the 5Ј-end of the RNA acceptor to form an inverted (5Ј)-(5Ј) triphosphate bridge structure, GpppN. (Fig. 3A) . In the linear range of Mce1-dependence, ϳ9% of the input protein molecules were labeled with [ 32 P]GMP. Enzyme-[ 32 P]GMP complex formation by 0.05 M Mce1 was stimulated by Tat and Tat⌬2/36, but Tat48⌬ had no effect (Fig. 3B) . Optimal stimulation (4 -5-fold) was attained at a 2:1 molar ratio of Tat to Mce1 (Fig. 3C) . The activity of the autonomous guanylyltransferase domain Mce1-(211-597) was similarly stimulated by Tat and Tat⌬2/36, but not Tat48⌬ (data not shown). Tat had no stimulatory effect on enzyme-GMP formation by purified recombinant yeast guanylyltransferase Ceg1 (data not shown). These results indicate that Tat interaction with Mce1 stimulates the guanylyltransferase activity of mammalian capping enzyme and the Tat domain from amino acids 37-86 suffices for this function.
Tat Stimulates the RNA Triphosphatase Activity of Mammalian Capping Enzyme-The RNA triphosphatase domain of mammalian capping enzyme displays extensive amino acid sequence similarity to protein tyrosine phosphatases and dualspecificity protein phosphatases. By analogy to the protein phosphatases, it is proposed that mammalian RNA triphosphatase executes a two-step phosphoryl transfer reaction involving a covalent enzyme-(cysteinyl-S)-phosphate intermediate (19, 34, 35 (Fig. 4A) . The titration profile of the isolated triphosphatase domain Mce1-(1-210) was more sigmoidal, but the slope of the curve in the linear range (4 -12 nM enzyme) was similar to that of Mce1 (Fig. 4A) nM Tat (Fig. 4B) . Note that Tat by itself had no detectable RNA triphosphatase activity at the highest level of input Tat used in this experiment (data not shown). The remarkable finding was that Tat did not stimulate RNA ␥-phosphate hydrolysis by 5 nM of the N-terminal RNA triphosphatase domain Mce1-(1-210), which catalyzed a similar level of basal RNA hydrolysis as 3 nM Mce1 (Fig. 4B) .
To investigate whether Tat interacts directly with the RNA triphosphatase domain, we established an affinity chromatography assay using His-tagged capping enzyme domains immobilized on Ni 2ϩ -agarose beads (Fig. 5A) . The beads were incubated with HA-tagged Tat. After washing the beads with buffer to remove unbound protein, the bead-bound material was stripped from the beads with SDS, and the presence of HA⅐Tat in the SDS-eluate was detected by immunoblotting with anti-HA antibody. As shown in HA⅐Tat also bound to beads containing immobilized guanylyltransferase domain Mce1-(211-597) (lane 2). This experiment reciprocates the finding that soluble guanylyltransferase domain was bound to immobilized Tat (Fig. 2) .
The results presented thus far demonstrate that Tat interacts with the isolated RNA triphosphatase and guanylyltransferase domains of mammalian capping enzyme. Whereas Tatbinding stimulates the guanylyltransferase activity of Mce1 and the C-terminal domain, Tat-stimulation of the RNA triphosphatase reaction appears to occurs only in the context of the full-length Mce1.
Tat Stimulates RNA Cap Formation by Mce1-The enzymatic addition of an unlabeled cap guanylate to the 5Ј-end of an internally labeled RNA molecule results in a characteristic slowing of the electrophoretic mobility of the RNA, equivalent to about a 2-nucleotide increase in apparent chain length (36) . The change in mobility upon addition of capping enzyme has been used to detect cap formation on RNAs as long as 78 nucleotides (37) . Here we studied the complete capping reaction of Mce1 using a synthetic 17-mer triphosphate-terminated RNA substrate that was labeled internally with [ 32 P]GMP (Fig.  6A) . Incubation of 0.5 M RNA substrate with Mce1 in the presence of 50 M cold GTP and magnesium chloride resulted in transfer of GMP to the 5Ј-end, yielding a capped species that migrated more slowly than the input substrate RNA (Fig. 6B) . Formation of the capped species was dependent on inclusion of GTP in the reaction mixture (not shown). The extent of capping was proportional to input Mce1 and saturated at 0.4 M Mce1 with about 70% of the input RNA being capped (Fig. 6C) . In the linear range of enzyme-dependence, 1 pmol of RNA was capped per pmol of the Mce1.
The level of capping catalyzed by 50 nM Mce1 (1 pmol of input Mce1) was increased 6-fold by Tat (Fig. 6D) . The stimulation was Tat concentration-dependent and saturation was attained at a 4:1 molar ratio of Tat to Mce1. An identical capping stimulation profile was observed for the deletion mutant Tat⌬2/36 containing an intact RNA binding domain. Tat48⌬ containing the activation domain had no salutary effect on RNA capping (Fig. 6D) . The ability of Tat or its component domains to stimulate cap formation by Mce1 correlated perfectly with the capacity to bind to Mce1 (Fig. 3) .
Tat Enhances TAR RNA Capping-Tat functions through TAR RNA to control an early step in transcription elongation that depends on the Pol II CTD (26, 38) . In light of our findings that Tat stimulates mammalian capping enzyme, we envisioned that Tat might enhance the capping of its target TAR mRNA, which might otherwise be inefficiently capped because the 5Ј-end is encompassed within a stable RNA duplex (39) . To test this hypothesis, we prepared internally labeled Non-TAR RNA (17-mer) and TAR RNA (29-mer) substrates (Fig. 7A) and tested them for capping in the same reaction mixtures with limiting Mce1. Capping reactions containing 75 nM Mce1 and 250 nM each of the Non-TAR and TAR substrates were supplemented with increasing amounts of Tat protein and the labeled products were resolved by PAGE (Fig. 7B) . In a competitive situation in the absence of Tat (Fig. 7B, lane 2) , Mce1 favored the Non-TAR substrate (1 pmol of cap formed) over the TAR substrate (0.3 pmol of cap formed) (Fig. 7C) . Tat enhanced capping of both Non-TAR and TAR RNA substrates at a 2:1 ratio of Tat to Mce1 (Fig. 7C ). Yet, the relative Tat stimulation of capping of the TAR RNA (5-fold) was greater than that of the Non-TAR substrate (2-fold).
DISCUSSION
Selective targeting of caps to Pol II transcripts in vivo is achieved, at least in part, through direct physical interaction of the capping apparatus with the phosphorylated CTD of Pol II. In addition to recruiting capping enzyme to the Pol II elongation complex, the phosphorylated CTD stimulates the guanylyltransferase activity of the mammalian capping enzyme (21) . This simple and appealing model for targeting and regulation of capping is belied by the underlying complexity of CTD phosphorylation (and dephosphorylation) and by mounting evidence that regulation of transcription elongation is a key facet of cotranscriptional mRNA processing. The data presented here illuminate a new pathway of capping enzyme recruitment and activation by the HIV Tat protein. Our findings contribute to an emerging picture of how elongation and processing are coupled, especially during HIV gene expression. In mammalian cells, the timely acquisition of the cap may promote subsequent mRNA-specific processing steps (splicing and polyadenylation) and protect the nascent mRNA from exonucleolytic decay. A clear advantage would accrue from a mechanism whereby capping is restricted to Pol II complexes that are committed to productive elongation, insofar as the capping of short transcripts that are subsequently aborted and released would generate a population of non-coding capped RNAs that could compete with bona fide mRNAs in cap-dependent transactions. CTD hyperphosphorylation has often been correlated with the establishment of a stable elongation complex, but there is little information as to the exact nature of the phosphorylation array at any point in the transcription cycle and there is still uncertainty concerning the relative contributions of different CTD kinases (TFIIH and P-TEFb) to the establishment and remodeling of the CTD phosphorylation array. The timing during early elongation of the critical CTD phosphorylation steps that permit capping enzyme recruitment are not well defined and may even vary for different transcription units. Although it is clear that short nascent transcripts (on the order of 30 nucleotides) can be capped, such results reflect the action of the capping enzymes on arrested polymerase elongation complexes, where there is no kinetic competition between ongoing elongation and capping. The RNA size threshold for capping in this experimental setting simply reflects the steric constraints on capping of RNA chains held within the RNA binding pocket of the polymerase. The unimpeded rate of elongation by RNA polymerase (ϳ20 nucleotides/s) is faster than estimates of the rates of the RNA triphosphatase and guanylyltransferase reactions (reviewed in ref. (40)), which sets up a situation in which RNA polymerase might "outrun" the capping enzyme. It is not known whether capping enzyme has a narrow or wide window for action on nascent 5Ј ends in vivo, i.e. whether capping enzyme would dissociate from the elongation complex after polymerase has proceeded a certain distance down the transcription unit.
Thus, there is advantage in imposing an elongation checkpoint to maximize the opportunity for the capping apparatus to bind the elongation complex. This scenario has been studied most thoroughly for HIV transcription, where the negative elongation factor DSIF induces an elongation block that is overcome by P-TEFb, a cyclin-dependent protein kinase that phosphorylates the CTD (27) (Fig. 8) . One key function of the Tat-TAR RNA complex is to recruit P-TEFb to the nascent HIV mRNA through an interaction of the cyclin T1 subunit of PTEFb with the activation domain of Tat. The CTD kinase function of P-TEFb is essential for Tat-TAR stimulation of HIV transcription, whereas the CTD kinase activity of TFIIH is apparently not critical for overriding the effects of DSIF (41, 42) , Indeed, although TFIIH and P-TEFb are both associated with very early HIV elongation complexes halted at position ϩ14, TFIIH dissociates by the time the polymerase moves to position ϩ30 or ϩ36 (prior to elaboration of the TAR site in the nascent RNA), whereas P-TEFb remains associated with the elongation complex at least up to position ϩ79 when TAR is formed (43, 41) . The presence of Tat triggers a new round of P-TEFb-catalyzed CTD phosphorylation on elongation complexes at position ϩ79 (41) .
An exciting connection between Tat, P-TEFb, and cap formation emerges from the recent report that Tat alters the phosphorylation site-specificity of P-TEFb in the context of the HIV transcription complex. P-TEFb phosphorylates Ser-2 of the CTD heptad in the absence of Tat, but it phosphorylates both Ser-2 and Ser-5 when Tat is present (41) . CTD phosphorylation on either Ser-2 or Ser-5 suffices to bind mammalian capping enzyme, but CTD-stimulation of capping activity is specific for the Ser-5-PO 4 CTD array (21) . Thus, the Tat/TAR/P-TEFb complex helps craft a CTD array that both recruits and activates Mce1.
Here we have shown that Tat spearheads a second and novel pathway of capping enzyme recruitment and activation via a direct physical interaction between Tat and Mce1. Unlike, the Tat-P-TEFb interaction, which requires the N-terminal transactivation domain of Tat, the binding of Tat to capping enzyme is via the C-terminal domain that includes the TAR RNA binding site. The Tat-Mce1 interaction results in a significant stim- ulation of the guanylyltransferase and triphosphatase activities of Mce1 and it thereby enhances the efficiency of cap formation on defined RNA substrates. Tat is unique among the recently discovered regulators of mammalian capping enzyme because as it is the only factor that up-regulates the triphosphatase component of the bifunctional enzyme. The effects of Ser-5-PO 4 CTD and hSpt5 on Mce1 are limited to stimulation of the guanylyltransferase (21, 23) . Tat-stimulation of Mce1 triphosphatase activity occurs in the context of the native twodomain enzyme, but not with the isolated N-terminal triphosphatase component, even though Tat can bind to the isolated triphosphatase domain. Thus, it appears that contacts of Tat to both domains of Mce1 are needed to elicit the increase in triphosphatase activity. In contrast, Tat is equally capable of stimulating the guanylyltransferase activity of the full-length Mce1 and its isolated C-terminal domain. Ser-5-PO 4 CTD can also up-regulate either Mce1 or the guanylyltransferase domain, but hSpt5 (which is a subunit of DSIF) only affects the activity of full-length Mce1.
There are now 3 possible pathways of up-regulating HIV mRNA capping involving factors that are known to be associated with the HIV transcription complex: (i) direct Tat activation of Mce1; (ii) CTD-PO 4 activation of Mce1, via Tat-stimulation of the CTD kinase activity of P-TEFb; (iii) DSIF activation of Mce1 via its hSpt5 subunit (Fig. 8) . There is potential for cross-talk between these pathways, insofar as P-TEFb phosphorylation of CTD clearly affects DSIF function and P-TEFb is also capable of phosphorylating the hSpt5 subunit of DSIF (44) . Phosphorylation of hSpt5 by P-TEFb has been reported to block its ability to elicit a transcription elongation block (44) . The effects of hSpt5 phosphorylation on its interaction with the capping enzyme are unclear. The attractive feature of the direct Tat-Mce1 activation pathway in HIV gene expression is that it is independent of CTD phosphorylation status and provides a means for direct and specific recruitment of Mce1 to the nascent HIV transcript containing bound Tat.
Why might HIV go to such lengths to employ Tat to recruit and activate Mce1? The formation of stable RNA secondary structures in which the 5Ј end of the HIV transcript is encompassed within a duplex stem may limit access of the 5Ј terminus to the active sites of the capping enzyme (39) . Such a stem structure is formed by nascent HIV mRNA even prior to the synthesis of the TAR sequence and, although the secondary structure changes after TAR is formed, the 5Ј end remains held within a duplex stem (45) . We observed a structured TAR substrate was capped less effectively by purified Mce1 than an RNA with no apparent secondary structure. Although Tat stimulated the capping of both Non-TAR and TAR RNAs, the-foldstimulation of the structured TAR substrate was greater than that of the unstructured transcript. Thus regulation of capping by Tat would have the most impact where capping is inherently weak. Finally, a Tat-dependent enhancement of mRNA cap formation may account for the finding that Tat stimulates the translation of mRNAs synthesized from the HIV transcription unit (46) .
